SCM
SCMP

Stonepine Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Stonepine Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-284,002
Closed -$3.85M – 25
2016
Q4 		$3.85M Buy
+284,002
New +$3.96M 2.29% 14
2016
Q3 		– Sell
-213,860
Closed -$2.35M – 23
2016
Q2 		$2.35M Buy
213,860
+208,632
+3,991% +$2.34M 2.41% 13
2016
Q1 		$57K Buy
+5,228
New +$66.1K 0.07% 16

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonepine Capital Management's SCMP Position: Q1 2017 in Review

Stonepine Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 284,002 shares — an estimated $3.85M sold.

Stonepine Capital Management first reported a position in SCMP in Q1 2016 and held it in 3 quarters. The position peaked at $3.85M in Q4 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • Stonepine Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Stonepine Capital Management sold 284,002 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $3.85M.
  • Stonepine Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • Stonepine Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $3.85M in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Stonepine Capital Management's 13F filing for Q1 2017, filed 12 May 2017.